Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Aslan Pharma of Singapore Raises $12 Million for In-licensing

publication date: Apr 27, 2011
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Aslan Pharmaceuticals Pte. Ltd. of Singapore announced a $12 million Series A funding, which it will use to in-license novel medicines. The company’s business model is to partner development-stage drugs that are 6-12 months from entering the clinic, perform Phase I and II studies in Asia to obtain Proof of Concept, and then out-license the compounds back to partners for global development. More details....

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...